Abstract
At an interim meeting on August 13, 2014, just in time for the upcoming respiratory season, CDC's Advisory Committee on Immunization Practices (ACIP) voted 13 to 2 to recommend the pneumococcal conjugate vaccine PCV13 (Prevnar 13 - Pfizer) for adults aged 65 years and older. The committee had delayed discussion and a vote at its June meeting to gather more information on the use of PCV13 in this patient population (for details, see page 21 of the August issue).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
